Urinary Methotrexate Dosage in Rheumatoid Arthritis, in Patients Treated for at Least 6 Months: a Potential Marker of Adherence

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2024 May 21

PMID 38772677

Authors

Noemie Theate

Marion Geoffroy

Lukshe Kanagaratnam

Claire Gozalo

Isabelle Charlot

Lois Bolko

Ambre Hittinger-Roux

Zoubir Djerada

Jean-Hugues Salmon

Affiliations

Soon will be listed here.

Abstract

Objectives: Non-adherence to rheumatoid arthritis (RA) treatments must be identified. A methotrexate (MTX) urinary dosage (METU) was recently developed. The aim of our study was to assess adherence to MTX in RA using METU in real-life conditions and to compare it with indirect adherence measurement technics.

Methods: We performed a cross-sectional study at Reims University Hospital. We included over 18-year-old patients with RA treated by MTX for more than 6 months. Patients were invited to complete demographic, clinical and psychological questionnaires and adherence measurement technics (Compliance Questionnaire of Rheumatology (CQR) and Medication Possession Ratio (MPR)). A urinary sample was collected to measure MTX and information about tolerance was evaluated through Methotrexate Intolerance Severity Score.

Results: 84 patients were included, 26 using oral MTX, 58 subcutaneous (SC) MTX. Among them, 73% were female, mean age was 61.5 years, MTX mean dose was 15 mg/week and 61.9% were treated by biological DMARDs (Disease Modifying Antirheumatic Drugs). 77 patients (91.7%) were adherent to treatment according to METU, whereas MPR and CQR reported less adherence (69.5% and 61.9%, respectively). MPR and METU were not significantly different in SC MTX users (p=0.059). Non-adherent patients had a higher number of tender joints and C reactive protein value (p<0.05).

Conclusion: This is the first largest study evaluating MTX adherence in patients with RA using a urinary dosage. We identified that indirect adherence measurements did not reflect real-life adherence. It would be appreciable to realise METU, in a new study, in patients with RA with unexplained response to treatment, to consider it before escalating therapeutic strategy.

References

Wei L, Champman S, Li X, Li X, Li S, Chen R . Beliefs about medicines and non-adherence in patients with stroke, diabetes mellitus and rheumatoid arthritis: a cross-sectional study in China. BMJ Open. 2017; 7(10):e017293. PMC: 5640055. DOI: 10.1136/bmjopen-2017-017293. View

Sperber C, Samarasinghe S, Lomax G . An upper and lower bound of the Medication Possession Ratio. Patient Prefer Adherence. 2017; 11:1469-1478. PMC: 5590759. DOI: 10.2147/PPA.S136890. View

Neame R, Hammond A . Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(6):762-7. DOI: 10.1093/rheumatology/keh587. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M . EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021; 81(1):20-33. PMC: 8761998. DOI: 10.1136/annrheumdis-2021-220973. View

Salt E, Wiggins A, Harrington N, Rayens M, Lohr K . Evaluation of a medication optimization intervention and predictors of medication adherence, patient satisfaction and medication adverse events in patients with rheumatoid arthritis. Musculoskeletal Care. 2021; 20(2):321-329. DOI: 10.1002/msc.1590. View

Modi A, Ingerski L, Rausch J, Glauser T, Drotar D . White coat adherence over the first year of therapy in pediatric epilepsy. J Pediatr. 2012; 161(4):695-9.e1. PMC: 3426618. DOI: 10.1016/j.jpeds.2012.03.059. View

van der Togt C, van den Bemt B, Aletaha D, Alten R, Chatzidionysiou K, Galloway J . Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 2023; 9(1). PMC: 9990692. DOI: 10.1136/rmdopen-2022-002898. View

Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S . Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol. 2016; 35(5):1341-5. DOI: 10.1007/s10067-016-3243-8. View

10.

Geoffroy M, Gozalo C, Konecki C, Pauvele L, Hittinger A, Theate N . A new pharmacokinetic model of urinary methotrexate to assess adherence in rheumatoid arthritis. Biomed Pharmacother. 2023; 168:115620. DOI: 10.1016/j.biopha.2023.115620. View

11.

Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M . Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. Int J Clin Pract. 2019; 73(7):e13375. DOI: 10.1111/ijcp.13375. View

12.

Bluett J, Riba-Garcia I, Hollywood K, Verstappen S, Barton A, Unwin R . A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence. Analyst. 2015; 140(6):1981-7. DOI: 10.1039/c4an02321h. View

13.

Durcan L, Clarke W, Magder L, Petri M . Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015; 42(11):2092-7. PMC: 4630115. DOI: 10.3899/jrheum.150379. View

14.

Fahrni M, Saman K, Alkhoshaiban A, Naimat F, Ramzan F, Isa K . Patient-reported outcome measures to detect intentional, mixed, or unintentional non-adherence to medication: a systematic review. BMJ Open. 2022; 12(9):e057868. PMC: 9486224. DOI: 10.1136/bmjopen-2021-057868. View

15.

Curtis J, Bykerk V, Aassi M, Schiff M . Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. J Rheumatol. 2016; 43(11):1997-2009. DOI: 10.3899/jrheum.151212. View

16.

Chausset A, Fargeix T, Pereira B, Echaubard S, Duquesne A, Desjonqueres M . MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance. Clin Rheumatol. 2017; 36(6):1281-1288. DOI: 10.1007/s10067-017-3638-1. View

17.

Stocco G, Londero M, Campanozzi A, Martelossi S, Marino S, Malusa N . Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. J Crohns Colitis. 2010; 4(5):599-602. DOI: 10.1016/j.crohns.2010.04.003. View

18.

Ko K, Moon S, Koh J, Pae C, Min J . Contribution of Personality Traits, Psychological Factors, and Health-Related Quality of Life to Medication Adherence in Patients with Rheumatoid Arthritis. Yonsei Med J. 2020; 61(5):406-415. PMC: 7214105. DOI: 10.3349/ymj.2020.61.5.406. View

19.

Bluett J, Riba-Garcia I, Verstappen S, Wendling T, Ogungbenro K, Unwin R . Development and validation of a methotrexate adherence assay. Ann Rheum Dis. 2019; 78(9):1192-1197. PMC: 6788879. DOI: 10.1136/annrheumdis-2019-215446. View

20.

Pasma A, den Boer E, van t Spijker A, Timman R, van den Bemt B, Busschbach J . Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. Rheumatology (Oxford). 2016; 55(10):1812-9. DOI: 10.1093/rheumatology/kew247. View